In the reshuffle resulting from Novartis’s purchase of Morphosys it seems Incyte, which bought the anti-CD19 MAb Monjuvi, got the better end of the bargain. Several months after toplining a win for the Inmind study in follicular lymphoma, Incyte has bagged an ASH late-breaker; the trial tests Monjuvi plus Rituxan and Revlimid in relapsed/refractory disease. Incyte has said it plans to file Monjuvi in follicular lymphoma by the year end, and the remaining days of 2024 should also see data from Monjuvi’s confirmatory B-Mind trial in relapsed diffuse large B-cell lymphoma. Monjuvi has accelerated approval in second-line DLBCL based on the L-Mind study, which found a 55% ORR. A bigger prize would be first-line DLBCL, where Monjuvi is being given alongside Revlimid and R-CHOP chemotherapy in the Frontmind trial; data are due in 2025. Monjuvi sold just $86m in the first nine months of 2024, but Incyte only paid $25m for full rights (in addition to a $750m licensing fee in 2020). CD19 has come back onto the agenda recently, but much of the interest has been around T-cell engagers, with Merck & Co tapping China’s Curon and AstraZeneca taking an in-house contender into phase 3. Inmind study results in follicular lymphoma Monjuvi + Rituxan + RevlimidRituxan + RevlimidmPFS (investigator-assessed)22.4 months13.9 monthsHR: 0.43; p<0.0001mPFS (centrally assessed)NR16.0 monthsHR: 0.41; p<0.0001PET-CR rate49%40%p=0.029ORR84%72%p=0.0014OSHR: 0.59; immature, “trend in favour” of MonjuviSource: ASH 2024 late-breaking abstract. ASH will take place on 7-10 December in San Diego.
In the reshuffle resulting from Novartis’s purchase of Morphosys it seems Incyte, which bought the anti-CD19 MAb Monjuvi, got the better end of the bargain. Several months after toplining a win for the Inmind study in follicular lymphoma, Incyte has bagged an ASH late-breaker; the trial tests Monjuvi plus Rituxan and Revlimid in relapsed/refractory disease. Incyte has said it plans to file Monjuvi in follicular lymphoma by the year end, and the remaining days of 2024 should also see data from Monjuvi’s confirmatory B-Mind trial in relapsed diffuse large B-cell lymphoma. Monjuvi has accelerated approval in second-line DLBCL based on the L-Mind study, which found a 55% ORR. A bigger prize would be first-line DLBCL, where Monjuvi is being given alongside Revlimid and R-CHOP chemotherapy in the Frontmind trial; data are due in 2025. Monjuvi sold just $86m in the first nine months of 2024, but Incyte only paid $25m for full rights (in addition to a $750m licensing fee in 2020). CD19 has come back onto the agenda recently, but much of the interest has been around T-cell engagers, with Merck & Co tapping China’s Curon and AstraZeneca taking an in-house contender into phase 3.
Inmind study results in follicular lymphoma
| Monjuvi + Rituxan + Revlimid | Rituxan + Revlimid |
|---|
| mPFS (investigator-assessed) | 22.4 months | 13.9 months |
| HR: 0.43; p<0.0001 |
| mPFS (centrally assessed) | NR | 16.0 months |
| HR: 0.41; p<0.0001 |
| PET-CR rate | 49% | 40% |
| p=0.029 |
| ORR | 84% | 72% |
| p=0.0014 |
| OS | HR: 0.59; immature, “trend in favour” of Monjuvi |
ASH will take place on 7-10 December in San Diego.
